Presidential Executive Order Reclassifies Cannabis, Accelerating DeFloria's Phase 2 Autism Drug Development
核心洞察
A Presidential Executive Order reclassifying cannabis from Schedule I to Schedule III is expected to accelerate cannabinoid medical innovation and reduce regulatory barriers for pharmaceutical companies.
DeFloria Inc. (搜索) has advanced its cannabinoid-based investigational drug AJA001 through FDA's botanical drug pathway, completing Phase 1 trials and receiving authorization for Phase 2 studies targeting autism (搜索)-related irritability (搜索).
The rescheduling is anticipated to unlock federal research funding, increase academic collaboration, and attract greater institutional investment in cannabinoid drug development.
A Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III represents a pivotal moment for cannabinoid pharmaceutical development, particularly benefiting companies like DeFloria Inc. (搜索), which is advancing a leading cannabinoid-based investigational new drug through FDA's botanical drug pathway for autism (搜索)-related irritability (搜索).
DeFloria's Clinical Progress
DeFloria has achieved significant regulatory milestones with its AJA001 oral solution, including a cleared botanical IND application and "Study May Proceed" letter from the FDA. The company has completed a Phase 1 PK/PD clinical trial, demonstrating safety and a well-tolerated dosing profile, and received FDA authorization to initiate a Phase 2 clinical program evaluating AJA001 for irritability (搜索) associated with autism (搜索).
These achievements establish DeFloria at the forefront of developing an FDA-approved botanical cannabinoid drug, with the company now positioned to initiate Phase 2 clinical trials at what CEO Jared Stanley describes as "exactly the right moment."
Impact of Regulatory Rescheduling
The shift to Schedule III is expected to unlock significant new opportunities across research, academia, and capital markets. Key anticipated benefits include expanded federal research funding and reduced barriers for academic cannabinoid studies, increased collaboration with medical institutions on controlled trials, and greater institutional investment as regulatory and compliance risk decreases.
"This policy shift opens the door to an entirely new level of potential investment, partnership, and scientific collaboration," said Jared Stanley, CEO of DeFloria. "DeFloria is initiating the Phase 2 clinical program at exactly the right moment - as federal recognition of cannabinoid medicine can unlock capital inflows and strategic interest across the biopharmaceutical industry."
Strategic Positioning for Partnerships
The rescheduling reduces long-standing barriers for pharmaceutical companies evaluating cannabinoid-based drug candidates. DeFloria's standardized botanical composition, robust safety data, and advanced clinical status make it one of the most partnership-ready platforms in the emerging cannabinoid drug sector.
Company Background and Legacy
DeFloria, formed in 2023 by AJNA BioSciences PBC (搜索) and Charlotte's Web Holdings (搜索), Inc. with a subsidiary of British American Tobacco plc (搜索) as lead investor, represents the continuation of a patient-centered movement that began more than a decade ago with the Stanley Brothers and their founding of Charlotte's Web. The company harnesses proprietary full-spectrum hemp genetics, FDA-compliant manufacturing, and deep cannabinoid science to deliver therapies through the FDA Botanical Drug Pathway.
The Executive Order represents pivotal federal acknowledgment of the therapeutic value of cannabinoids and validates this patient-centered approach that has evolved into sophisticated pharmaceutical development programs targeting specific medical conditions.